Immunome Inc (IMNM) — Strategic Asset Allocation Index
Immunome Inc (IMNM) has a Strategic Asset Allocation Index of 12.9% as of June 2023. Strategic assets (PP&E of $1.20 Million plus long-term investments of $-) total $1.20 Million, measured against net assets of $9.34 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. See Immunome Inc (IMNM) balance sheet quality index to measure how much of total assets are equity-financed.
SAAI
Strategic Assets
PP&E
Net Assets
Immunome Inc Strategic Asset Allocation Index (2020–2022)
This chart shows how Immunome Inc's Strategic Asset Allocation Index has evolved across 3 annual periods from 2020 to 2022. As of June 2023, the index stands at 12.9%, representing strategic assets of $1.20 Million against net assets of $9.34 Million USD. For live market cap and overall valuation, see IMNM stock market capitalisation.
Annual Strategic Asset Allocation Index for Immunome Inc (2020–2022)
The table below presents the year-by-year Strategic Asset Allocation Index for Immunome Inc from 2020 to 2022, covering 3 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. See net assets of Immunome Inc for net asset value and shareholders' equity analysis.
| Year | SAAI | Strategic Assets (USD) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 4.1% | $681.00K | $681.00K | $- | $16.65 Million | ▲ +2.3 pp |
| 2021 | 1.8% | $855.00K | $855.00K | $- | $48.19 Million | ▼ -1.9 pp |
| 2020 | 3.7% | $1.53 Million | $1.53 Million | $- | $41.34 Million | — |